期刊文献+

新诊断2型糖尿病患者尿Smad3蛋白水平及其相关因素 被引量:1

Urinary Smad3 protein level in newly diagnosed patients with type 2 diabetes mellitus and its related factors
原文传递
导出
摘要 目的探讨新诊断2型糖尿病(T2DM)患者尿Smad3蛋白水平及其影响因素。方法选取新诊断T2DM患者68例,采用酶联免疫吸附法(ELISA)检测新诊断T2DM患者尿中Smad3蛋白水平,并测定患者的空腹血糖和血脂。按尿微量白蛋白分为正常白蛋白尿组(37例)和微量蛋白尿组(31例),比较两组患者中尿Smad3蛋白水平,采用相关和线性回归分析法分析新诊断T2DM患者尿Smad3蛋白的影响因素。结果与正常蛋白尿组比较,微量白蛋白尿组患者的空腹血糖、糖化血红蛋白(HbA1C)、总胆固醇、低密度脂蛋白胆固醇、血尿酸及尿Smad3蛋白水平均较高,差异均有统计学意义(P<0.05);新诊断T2DM患者尿Smad3蛋白与HbA1C、总胆固醇、血尿酸和尿微量白蛋白呈正相关;线性回归分析显示,HbA1C和尿微量白蛋白是新诊断T2DM患者尿Smad3蛋白的独立影响因素(β值分别为0.106、0.003,P<0.01,P<0.05)。结论尿Smad3蛋白水平可以作为新诊断T2DM患者肾脏损伤的一个评估指标。 Objective: To explore urinary Smad3 protein level and its related factors in newly diagnosed patients with type 2 diabetes mellitus(T2DM). Methods The urinary Smad3 protein level was measured by enzyme linked immunosorbent assay(ELISA) in68 newly diagnosed patients with T2 DM,also the levels of fasting plasma glucose and blood lipid were detected. According to microalbuminuria,68 subjects were divided into normal albumuria group(37 cases) and microalbuminuria group(31 cases).The urinary Smad3 protein levels between two groups were compared. The Pearson and linear regression analysis was used to analyze the influencing factors for urinary Smad3 protein levels in patients with T2 DM. Results As compared with normal albumuria group,the levels of fasting blood glucose,glycated hemoglobin(HbA1C),total cholesterol,low density lipoprotein cholesterol,serum uric acid and urinary Smad3 protein in microalbuminuria group enhanced significantly(P〈0.05). The urinary Smad3 protein levels were correlated positively with the levels of HbA1 C,total cholesterol,serum uric acid and urinary microalbumin in newly diagnosed patients with T2 DM. The linear regression analysis showed HbA1 Cand urinary microalbumin were independent influencing factors for the urinary Smad3 protein levels in newly diagnosed patients with T2DM(β value was0.106 and 0.003,respectively,P〈0.01 or P〈0.05). Conclusion The urinary Smad3 protein can serve as an index to evaluate the renal damage in newly diagnosed patients with T2 DM.
出处 《中国慢性病预防与控制》 CAS 2014年第4期398-400,共3页 Chinese Journal of Prevention and Control of Chronic Diseases
基金 湖南省科学技术厅2012年科技计划项目(2012SK3147)
关键词 2型糖尿病 糖尿病肾病 SMAD3蛋白 白蛋白尿 Diabetes mellitus, type 2 Diabetic nephropathy Smad3 protein Albuminuria
  • 相关文献

参考文献11

  • 1Loeffler I, Wolf G. Transforming growth factor-beta and the progression of renal disease [ J ]. Nephrol Dial Transplant, 2014,29 (Suppl 1 ): i37-i45.
  • 2Lan HY, Chung AC. Transforming growth factor-beta and Smads[J]. Contrib Nephrol, 2011,170( 1 ):75-82.
  • 3Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system[J]. EMBO J, 2000,19(8 ):1745-1754.
  • 4Furuse Y, Hashimoto N, Maekawa M, et al. Activation of the Smad pathway in glomeruli from a spontaneously diabetic rat model, OLETF rats[J]. Nephron Exp Nephrol, 2004,98(3):e100-108.
  • 5Isono M, Chen S, Hong SW, et al. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibroneetin in mesangial cells [J]. Biochem Biophys Res Commun, 2002,296(5 ):1356-1365.
  • 6Hong SW, Isono M, Chen S, et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse [J ]. Am J Pathol, 2001,158(5 ):1653-1663.
  • 7Lan HY. Transforming growth factor-beta/Smad signalling in diabetic nephropathy[ J ]. Clin Exp Pharmacol Physiol, 2012,39( 8 ):731-738.
  • 8Li J, Qu X, Yao J, et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy [J ]. Diabetes, 2010,59 ( 10):2612-2624.
  • 9Yang F, Huang XR, Chung AC, et al. Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition [J]. J Pathol, 2010,221(4):390-401.
  • 10Wang A, Ziyadeh FN, Lee EY, et al. Interference with TGF-beta sig- naling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria[ J ]. Am J Physiol Renal Physiol, 2007, 293 (5):F1657-1665.

二级参考文献16

  • 1Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis, 2003, 41 :S19-S21.
  • 2Lan HY. Transforming growth factor-β/Smad signalling in diabetic nephropattly. Clinical and Experimental Pharmacology and Physiology , 2012, 39:731-738.
  • 3Sato H, Iwano M, Akai Y, et al. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol, 1998,18:490-494.
  • 4Ellis D, Forrest KY, Erbey J, et al. Urinary measurement of transforming growth factor-beta and type 1V collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem,1998, 44:950-956.
  • 5Furuse Y, Hashimoto N, Maekawa M, et al. Activation of the Smad pathway in glomeruli from a spontaneously diabetic rat model, OLETF rats. Nephron Exp Nephrol, 2004, 98: e100-e108.
  • 6Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk : is albumin excretion rate sufficient?. Diabetes, 2000, 49 : 1399-1408.
  • 7Li JH, Huang XR, Zhu HJ, et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: Implications for diabetic renal and vascular disease. FASEB J, 2004, 18 : 176-178.
  • 8Yang F, Huang XR, Chung AC, et al. Essential role for smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J Pathol, 2010, 221 : 390-401.
  • 9Chung AC, Zhang H, Kong YZ, et al. Advanced glycation end- products induce tubular CTGF via TGF-beta-independent smad3 signaling. J Am Soc Nephrol, 2010, 21: 249-260.
  • 10Phanish MK, Wahab NA, Colville-Nash P, et al. The differential role of Smad2 and smad3 in the regulation of pro-fibrotic TGFbetal responses in human proximal-tubule epithelial cells. Biochem J, 2006, 393 : 601-607.

共引文献5

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部